POSITION PAPER

Treatment failure in osteoporosis

A Diez-Perez¹, JD Adachi², D Agnusdei³, J P Bilezikian⁴, JE Compston⁵, SR Cummings⁶, R Eastell⁷, EF Eriksen⁸, J Gonzalez-Macias⁹, UA Liberman¹⁰, DA Wahl¹¹, E Seeman¹², JA Kanis¹³, C Cooper¹⁴ for the IOF CSA Inadequate Responders Working Group

Address for correspondence:
Adolfo Diez-Perez, M.D.
Department of Internal Medicine and Infectious Diseases
Hospital del Mar-IMIM
P. Maritim 25-29
08003 Barcelona, Spain
Tel: +34932483245
Fax: +34932483257
E-mail: adiez@parcdesalutmar.cat

This position paper has been endorsed by the Committee of Scientific Advisors of IOF
1 Hospital del Mar-IMIM, Autonomous University of Barcelona. RETICEF. Instituto Carlos III, Barcelona, Spain
2 Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
3 Eli Lilly and Co., Florence, Italy
4 Columbia University College of Physicians and Surgeons, New York, USA
5 Department of Medicine, Addenbrooke's Hospital, Cambridge University, UK
6 San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA
7 Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
8 Department of Endocrinology, Oslo University Hospital, and Faculty of Medicine, University of Oslo, Oslo, Norway
9 Department of Internal Medicine, Hospital Marqués de Valdecilla- IFIMAV, University of Cantabria, Santander. RETICEF. Spain
10 Department of Physiology & Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
11 International Osteoporosis Foundation, Nyon, Switzerland
12 Endocrine Centre, Austin Health, University of Melbourne, Melbourne, Australia
13 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
14 MRC Lifecourse Epidemiology Unit, University of Southampton, and NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford, UK
Mini abstract
Guidelines concerning the definition of failure of therapies used to reduce the risk of fracture are provided.

Abstract

Purpose To provide guidelines concerning the definition of failure of therapies used to reduce the risk of fracture.

Methods A working group of the Committee of Scientific Advisors of the International Osteoporosis Foundation was convened to define outcome variables that may assist clinicians in decision-making.

Results In the face of limited evidence, failure of treatment may be inferred when two or more incident fractures have occurred during treatment, when serial measurements of bone remodelling markers are not suppressed by antiresorptive therapy and where bone mineral density continues to decrease.

Conclusion The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.

Keywords: fractures · Osteoporosis · Treatment · Bone mineral density · Markers of bone turnover
Introduction

The efficacy of drug treatment in osteoporosis ultimately depends on the demonstration of a reduction in the risk of fracture. In some instances efficacy against fracture risk is assumed where increases in BMD in one clinical context (e.g. in men) are equivalent to the changes in bone mineral density (BMD) in another clinical setting where efficacy on fracture risk has previously been demonstrated (e.g. in postmenopausal osteoporosis) [1,2]. Although biochemical markers of bone turnover are not considered to provide end-points or outcome measures, they have proved useful in dose-finding for several interventions in phase 2 studies and are commonly incorporated as a pharmacodynamic secondary endpoint in phase 3 studies. Thus, for anti-resorptive treatments, efficacy is assumed by a significant reduction in fracture risk supported by an increase in BMD and a decrease in markers of bone turnover. The converse applies to an ineffective treatment.

The question arises whether these therapeutic agents are effective in all patients who adhere to a treatment regimen. This is not an easy question to resolve. Fractures occur in both placebo and actively treated patients. An effective intervention decreases the risk of fracture but does not eliminate the risk. Typically, risk reductions are in the range of 30-70% for vertebral fractures, 40-50% for hip fractures and 15-20% for non-vertebral fractures [3,4]. Thus fractures during the course of treatment cannot be taken as proof of treatment failure. The situation is no better for the response of BMD and the markers of bone turnover to treatment. In several studies, treatment seems to be equally effective irrespective of the increment induced in BMD or the suppression of markers of bone turnover [5,6]. In addition, patients that lose bone under treatment are reported to have a lower fracture risk compared to control patients that lose bone [7-9]. Such observations suggest that changes in BMD and bone turnover markers are imperfect surrogates for anti-fracture efficacy.

These issues are difficult enough in the context of clinical trials, but become impossible to resolve outside the trial environment when dealing with individual patients. Notwithstanding, physicians are commonly faced with treatment failures in the sense that for the patient, a fracture that arises while on treatment signifies a failure of treatment. The problem is compounded by some reimbursement agencies and health technology
assessments that categorise first and second line drugs [5,6]. Second line drug are recommended when first line agents fail.

Against this background, the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation considered that pragmatic advice was needed for medical practitioners who have to deal with treatment failure – or more accurately – perceived treatment failure. The Committee of Scientific Advisors of the International Osteoporosis Foundation set up a Working Group to discuss these issues and this paper reports its recommendations. The Working Group proposes that the response to treatment can be assessed using incident fractures, changes in bone mineral density and bone turnover markers (BTMs).

**Incident fracture**
Sustaining a fracture is always an undesirable outcome but treatments do not eliminate fracture risk, they reduce it. Thus, it is difficult to infer that a fragility fracture that occurs while on treatment for at least 6 month since its initiation means that treatment has failed. Conversely, the absence of an intercurrent fracture is no arbiter of successful treatment since the majority of placebo-treated patients will not sustain a fracture during the conduct of a typical phase 3 trial. In clinical trials, a second or third fracture during therapy is generally markedly reduced by 80-90% in comparison to the placebo treated [10-13]. In addition, the natural history of fracture events is that after the index fracture, the fracture risk decreases progressively with time [14-16]. These observations provide the rationale for the Working Group to recommend that the occurrence of a second fragility fracture be used to infer that treatment has failed. It is important to note that not all fracture sites are associated with osteoporosis [17,18]. These include fractures of the hand, skull, digits, feet and ankle fractures which appear to be less responsive to interventions for osteoporosis [19].

**Bone mineral density**
Osteoporosis is characterised by progressive loss of bone and BMD is a predictor of fracture risk [20,21]. It is therefore intuitively appealing to presume that an increase in BMD
represents a favourable response to treatment and, conversely, that a decrease in BMD during the course of treatment is a sign of failure of treatment.

The principal problem in assessing this issue is that rates of bone loss or gain are most often modest compared to the errors incurred in the measurement of BMD. For example, the rate of loss in BMD at the femoral neck in untreated women with postmenopausal osteoporosis is typically 1-2% per year, which is approximately the same as the precision error of the measurement of BMD at this site. The measurement error is greater when assessing change in BMD in an individual since a change in BMD requires at least two measurements of BMD to be made - each with the attendant errors of measurement. Thus, a change in areal BMD is, as expected, a weak predictor of fracture risk reduction [22-25].

The change in BMD that can be confidently detected is termed the least significant change (LSC). LSC depends upon the precision error of the technique applied and the confidence needed to assume a change. In clinical research, at least 95% confidence is demanded when inferring that a change has occurred. This is approximately 2.77 times the coefficient of variation (CV) using a two-sided test (Table 1). If one is assessing failure to respond, then a one-sided test (2.33 x the CV) is appropriate since in clinical practice only one of the possibilities of BMD variation is of concern, the decrease. Furthermore, an 80% confidence might be accepted. Then, the LSC with a one-tailed test would be 1.19 x the individual coefficient of variation.

In the context of clinical research, the CV of BMD estimates at the femoral neck or lumbar spine lie in the order of 1.0 to 1.6% [26,27]. In clinical practice, the CV is approximately 2% at the lumbar spine and 1.6% at the hip [28,29]. Thus, to be 95% confident that a decrease in BMD has taken place (i.e. a one-sided test) a change of 4-5% should have been observed. Decreases in BMD greater than the LSC at 95% confidence are rarely found in patients who adhere to therapy [30,31]. This forms the rationale for the Working Group to propose that a decrease in BMD greater than the LSC at 95% confidence is considered as an indicator of failure to respond to treatment.
Table 1. Derivation of least significant change (%) from the coefficient of variation (expressed as a percent) and the confidence assumed for the difference.

<table>
<thead>
<tr>
<th>Confidence %</th>
<th>Multiple of CV (CV 2%)</th>
<th>ΔLS BMD % (CV 1.6%)</th>
<th>ΔFN BMD % (CV 10%)</th>
<th>ΔPINP % (CV 10%)</th>
<th>ΔCTX % (CV 10%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-sided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>3.64</td>
<td>7.3</td>
<td>5.8</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>95</td>
<td>2.77</td>
<td>5.5</td>
<td>4.4</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td>90</td>
<td>2.33</td>
<td>4.7</td>
<td>3.7</td>
<td>23</td>
<td>23</td>
</tr>
<tr>
<td>85</td>
<td>2.04</td>
<td>4.1</td>
<td>3.3</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>80</td>
<td>1.81</td>
<td>3.6</td>
<td>2.9</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>One-sided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>3.29</td>
<td>6.6</td>
<td>5.3</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td>95</td>
<td>2.33</td>
<td>4.7</td>
<td>3.7</td>
<td>23</td>
<td>23</td>
</tr>
<tr>
<td>90</td>
<td>1.81</td>
<td>3.6</td>
<td>2.9</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>85</td>
<td>1.47</td>
<td>2.9</td>
<td>2.4</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>80</td>
<td>1.19</td>
<td>2.4</td>
<td>1.9</td>
<td>12</td>
<td>12</td>
</tr>
</tbody>
</table>

Markers of bone turnover

The treatment of osteoporosis with anti-resorptive agents is associated with an early decrease in markers of bone resorption and a later decrease in markers of bone formation. In the case of teriparatide (or PTH 1-84), the principal index of response is an increase in indices of bone formation. Several studies suggest that, in general, the larger the decrease in turnover markers with anti-resorptive agents, the greater the reduction in fracture risk [32-38]. Thus failure to observe a change in these response variables might be considered as a failure to respond to treatment.

Since a change in markers is the response variable, the same considerations apply to the measurement of change in marker values as apply to changes in BMD, discussed above. In the case of the markers, the precision error is much higher (5 to 10-fold greater) but is offset by the larger response to treatment. A further consideration is the many markers available, often measured with different technologies, each with different precision errors. The role of bone markers in monitoring response to treatment has been reviewed by the
International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine [39] and recommends that serum C-telopeptide of type I collagen (βCTX) and serum procollagen I N-propeptide (PINP) are considered as reference markers. The CVs provided by the manufacturers are 4.3-6.5% for P1NP and 1.3-4.3% for βCTX [38] but the inter-laboratory errors are larger [40]. Under clinical conditions a precision error of approximately 10% is estimated for both analytes [39] so that LSC estimates for serum βCTX and PINP are approximately 25% (see Table 1).

For these reasons, the Working Group propose that a decrease in βCTX and PINP less than the LSC at 95% confidence is considered as an indicator of failure to respond to treatment with anti-resorptive agents and that an increase in PINP less than the LSC at 95% confidence is considered as an indicator of failure to respond to treatment with parathyroid hormone peptides.

**Clinical assessment of response to treatment**

In a patient receiving treatment in whom no new fractures have occurred, BMD has increased and bone markers have decreased with antiresorptive treatment, to the extent expected from the intervention used (greatest with denosumab, least with raloxifene or calcium supplements), fracture risk is likely to be attenuated and the treatment should be maintained. If these response criteria are not fulfilled within a year of starting treatment, modification of treatment should be considered. This includes a review of adherence, which is the most likely reason for a poor response and a search for occult secondary causes of osteoporosis [41,42].

If adherence cannot be further improved and other causes of secondary osteoporosis are excluded, the Working Group recommends that treatment be changed in the following circumstances:

a) Two or more incident fragility fractures

b) One incident fracture and elevated serum βCTX or PINP at baseline with no significant reduction during treatment, a significant decrease in BMD, or both
c) Both no significant decrease in serum βCTX or PINP and a significant decrease in BMD.

Note that:

1. Fractures of the hand, skull, digits, feet and ankle are not considered as fragility fractures.
2. The overall decline in BMD should be in the order of 5% or more in at least two serial BMD measurements at the lumbar spine or 4% at the proximal femur.
3. Sequential measurement of markers of bone turnover should use the same assay. A significant response is a decline of 25% from baseline levels for anti-resorptive treatments, and 25% increase for anabolic agents (PTH) after 6 months. For anti-resorptive treatments, if baseline levels are not known, a positive response is a decrease below the average value of young healthy adults. It is assumed that the response is similar between men and women.
4. Falls are an important driver of fracture. Therefore this problem should be considered when analysing response to treatments.

No evidence is available on the effectiveness of alternative treatments when one has been deemed to have failed. Almost no studies have explored the issue and, therefore, the available data are scarce [43]. Some data based on indirect comparisons or surrogate endpoints can be of help [44-47]. Three general rules, based on the opinion of the Working Group, are recommended:
a) A weaker anti-resorptive is reasonably replaced by a more potent drug of the same class
b) An oral drug is reasonably replaceable by an injected drug
c) A strong anti-resorptive is reasonably replaceable by an anabolic agent

Discussion

The available evidence does not permit a firm assessment of the success or failure of a treatment. The recommendations that we make are therefore based on expert opinion that provides the lowest level of evidence. Nevertheless, pragmatic criteria for failure to respond
to treatment are a need for the practicing clinician. Three parameters that modify fracture risk and that are commonly measured in clinical practice are incident fractures, changes in BMD and changes in markers of bone turnover and form the basis of our recommendations. The recommendations themselves have the merit of being conservative. There is, however, a dearth of evidence that patients deemed to have failed treatment respond favourably to an alternative. This needs further research.

If failure of therapy is a real state in adherent patients, this may arise because treatment is offered too late in the natural history of the disorder when disruption of skeletal architecture is well advanced [42]. Studies are needed to relate structure to treatment-induced fracture outcomes so patients at high risk can be targeted early enough to prevent irreversible architectural losses. Whether or not individuals with high remodelling rates may require more potent remodelling suppressants, and patients with low remodelling require less potent anti-resorptive or anabolic agents is an open question. So too is whether patients with marked deterioration of microarchitecture require anabolic agents rather than anti-resorpitives.

We conclude that a significant minority of patients who adhere to treatment fail to respond to available treatments. The reasons for this remain uncertain. In some cases treatment has failed perhaps because the bone is too severely disrupted, in others the treatment may be inappropriate, perhaps failing to access remodelling sites in bone. Nevertheless, no treatments eliminate the risk of fragility fractures so that treatments will be perceived as failing in those who sustain a further fracture by patients, carers and physicians alike. This paper identifies the unmet need to identify the morphological basis for treatment failure and success, mechanisms of drug therapy that may contribute to failed therapy and so advance our understanding of how best to identify patients at need for treatment, the mechanisms responsible and target treatment in a reasoned disease specific and individualized fashion.

Acknowledgments
This working group has been funded by the International Osteoporosis Foundation.
Competing interests
A Diez-Perez has given lectures and provided advice for Novartis, Amgen, Lilly and MSD. His institution has received research grants from Amgen and Servier. JD Adachi has given lectures and is a consultant for Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Procter & Gamble, Roche, Sanofi Aventis, Warner Chilcott. D Agnusdei is an employee of Eli Lilly. J Bilezikian is a consultant for Amgen, Merck, Lilly and GlaxoSmithKline, gives lectures for Amgen, Lilly and has received research grant from Amgen. J Compston has no disclosure. S Cummings is consultant for Merck, Amgen and Lilly. R Eastell serves as a consultant, has received honoraria for speaking, and has received grant support from Amgen, AstraZeneca, California Pacific Medical Center, GlaxoSmithKline, Hologic, Kyphon Inc., Lilly Industries, Maxygen, Nastech Pharmaceuticals, Nestle Research Center, New Zealand Milk Limited, Novartis, Novo Nordisk, ONO-Pharma, Organon Laboratories, Osteologix, Pfizer, Procter & Gamble Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Servier, Shire, Tethys, TransPharma Medical Limited, Unilever, and Unipath. E Eriksen has given lectures and has provided advice for Novartis, Amgen, Eli Lilly and ISD. J González-Macías has given lectures and provided advice for Amgen, Lilly, Servier and MSD. U Liberman has given lectures for MSD. D Wahl declares no conflict of interest. E Seeman serves as advisory board member and gives lectures at symposia organized by several pharmaceutical companies including, variously Amgen, Warner Chilcott, MSD, Eli Lilly, Sanofi-Aventis, Novartis. J A Kanis receives research funding and consults with many companies involved with skeletal metabolism. C Cooper has received honoraria and consulting fees from Servier, Amgen, Eli Lilly, Merck, Medtronic and Novartis.
References

1. Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD, Division of Metabolism and Endocrine Drug Products, Food and Drug Administration, 1994


